TheBody.com/TheBodyPRO.com cover the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010)

ICAAC 2010 Newsroom

Conference Coverage at TheBody.com | ICAAC 2010 Web Highlights

Conference Coverage at TheBody.com

Once-Daily "Extended" Formulation of Nevirapine Holds Up Well in 48-Week Study Results (September 15, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
"Quad" Pill Continues to Impress in Week-48 Results; Cobicistat Moves Forward in Battle With Ritonavir (September 14, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
A Slice of Atazanavir, but Hold the Ritonavir: Switch to Unboosted Dose Still Effective After 120 Weeks, With Good Lipid Findings (September 12, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
Even Among Long-Term HIV Nonprogressors, Some Signs of Heightened Cardiovascular Risk Exist, U.S. Study Finds (September 12, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com

ICAAC 2010 Web Highlights

Study Closes Vicriviroc Story (September 15, 2010)
From MedPage Today
Switch to HIV Combo Pill May Improve Lipids (September 15, 2010)
From MedPage Today
Insulin Resistance Correlates With HCV Load and SVR in HCV/HIV-Coinfected (September 15, 2010)
From National AIDS Treatment Advocacy Project
GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy (September 15, 2010)
From National AIDS Treatment Advocacy Project
Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla (September 15, 2010)
From National AIDS Treatment Advocacy Project
High Rates of Bone Loss and Progression With HIV in Longitudinal Study (September 15, 2010)
From National AIDS Treatment Advocacy Project
Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir (September 15, 2010)
From National AIDS Treatment Advocacy Project
Raltegravir Re-Use Response After Failure Depends on Mutation Pattern (September 15, 2010)
From National AIDS Treatment Advocacy Project
Long-Term Outcomes Good After Coreceptor Switch in Maraviroc Failure (September 15, 2010)
From National AIDS Treatment Advocacy Project
Longer Antiretroviral Therapy Favors Return to Normal HDL-C (September 15, 2010)
From National AIDS Treatment Advocacy Project

VIEW ALL ARTICLES

Home

All Headlines

Previous Conferences

New! TheBody.com App

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.